Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, China.
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Future Oncol. 2022 May;18(14):1679-1689. doi: 10.2217/fon-2021-1304. Epub 2022 Feb 8.
This study aimed to assess survival and hematological prognostic indicators of patients with non-small-cell lung cancer (NSCLC). Through the Project Data Sphere portal, two phase III clinical trial datasets were downloaded to analyze survival outcomes and related risk factors. The median progression-free survival and overall survival of 756 patients with stage III-IV NSCLC were 6.2 and 14.2 months, respectively. In multivariate Cox analysis, high baseline neutrophil-lymphocyte ratio (NLR; ≥3.8) was associated with worse progression-free survival (hazard ratio: 1.37; p = 0.0004) and overall survival (hazard ratio: 1.65; p < 0.0001). In addition, it exerted an unfavorable impact on survival across multiple subgroups. NLR, a powerful inflammatory and immunologic indicator, is an independent prognostic indicator in patients with advanced NSCLC.
本研究旨在评估非小细胞肺癌（NSCLC）患者的生存和血液学预后指标。通过 Project Data Sphere 门户，下载了两个 III 期临床试验数据集，以分析生存结果和相关的危险因素。756 例 III 期-IV 期 NSCLC 患者的中位无进展生存期和总生存期分别为 6.2 个月和 14.2 个月。多变量 Cox 分析显示，基线中性粒细胞-淋巴细胞比值（NLR；≥3.8）与无进展生存期（危险比：1.37；p=0.0004）和总生存期（危险比：1.65；p<0.0001）更差相关。此外，它在多个亚组中对生存产生了不利影响。NLR 是一种强大的炎症和免疫指标，是晚期 NSCLC 患者的独立预后指标。
